{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:07:05Z","timestamp":1791389225223,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002739","name":"Aarhus Universitets Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009898","name":"Beckett Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.atherosclerosis.2026.120754","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:14:20Z","timestamp":1776957260000},"page":"120754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting"],"prefix":"10.1016","volume":"417","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-9034","authenticated-orcid":false,"given":"Johan Skov","family":"Bundgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Albertsen","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Hastrup","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia Rengtved","family":"Lundegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Erikstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Ahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Frikke- Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Halfdan","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bundgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Ghouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"44","key":"10.1016\/j.atherosclerosis.2026.120754_bib1","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120754_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.atherosclerosis.2026.120754_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2026.120754_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"9822","key":"10.1016\/j.atherosclerosis.2026.120754_bib5","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2026.120754_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120754_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.01.021","article-title":"Lipoprotein(a) and prothrombotic effects: evidence from a genetic association study","author":"Olmastroni","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib10","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","author":"Nordestgaard","year":"2016","journal-title":"JLR (J Lipid Res)"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120754_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-Reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120754_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad867","article-title":"C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project","volume":"45","author":"Arnold","year":"2024","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120754_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-Reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119211","article-title":"Interleukin-6 modifies lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort","author":"Mohammadnia","year":"2025","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120754_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-Reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2018.02.013","article-title":"Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters","volume":"70","author":"Del Giudice","year":"2018","journal-title":"Brain Behav Immun"},{"issue":"10289","key":"10.1016\/j.atherosclerosis.2026.120754_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"7726","key":"10.1016\/j.atherosclerosis.2026.120754_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"7982","key":"10.1016\/j.atherosclerosis.2026.120754_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120754_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120754_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddab023","article-title":"Genome-wide association study of circulating interleukin 6 levels identifies novel loci","volume":"30","author":"Ahluwalia","year":"2021","journal-title":"Hum Mol Genet"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2026.120754_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein","volume":"44","author":"Thomas","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120754_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00011-025-02058-9","article-title":"Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3\/IL-1\u03b2\/IL-6\/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 randomized trials","volume":"74","author":"Pan","year":"2025","journal-title":"Inflamm Res"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2026.120754_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"Van Der Valk","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120754_bib26","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120754_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2003.11.062","article-title":"Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation","volume":"43","author":"Conway","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","author":"Kang","year":"2021","journal-title":"Exp Mol Med"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120754_bib30","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J Lipid Res"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2026.120754_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2013.12.030","article-title":"Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a)","volume":"63","author":"Tsimikas","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120754_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-024-01267-7","article-title":"Anti-inflammatory therapies in atherosclerosis - where are we going?","volume":"27","author":"Punnanithinont","year":"2024","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120754_bib33","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/ATVBAHA.124.320990","article-title":"Potential influence of risk factor control on the association between lipoprotein(a) and atherosclerotic cardiovascular disease","volume":"44","author":"Ghouse","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120754_bib34","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2\/3","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:13:49Z","timestamp":1783084429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["S0021915026001206"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120754","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120754"}}